NAD+ patches have become a popular alternative to capsules, injections and intravenous drips. Many products are also sold as multi-ingredient patches containing berberine, among other things, and in some cases also moringa. Their appeal is easy to understand. A patch is convenient, requires neither swallowing capsules nor administering injections, and is often advertised as a way to deliver ingredients gradually and steadily over many hours.
However, convenience does not automatically mean the effective delivery of substances into the body.
The most important scientific question is whether unchanged NAD+ can penetrate the skin in biologically significant quantities. This is important because the chemical properties of NAD+ hinder passive transdermal absorption more than in the case of many drugs effectively used in patches.
In this article, we explain how NAD+ patches are supposed to work, what transdermal pharmacology says about their potential absorption, why NAD+ is often combined with berberine, how such patches are usually used, and how their evidence base compares to NAD+ capsules and injections.
How are NAD+ transdermal patches supposed to work?
The transdermal patch is designed to allow the active substance to penetrate from the skin's surface into deeper tissues, and ideally also into the systemic circulation.
The basic concept is simple.
Instead of swallowing the compound and subjecting it to the digestive tract, the active substance is placed in a skin-adhering patch that stays on for several hours.
Manufacturers often claim that this method can ensure gradual absorption while bypassing degradation in the digestive tract.
Transdermal technology in itself is not an experimental solution.
Well-known examples include nicotine patches, hormone patches, and certain painkillers.
However, the efficacy of transdermal delivery depends largely on the chemical properties of the specific molecule.
Some substances penetrate the skin relatively easily.
Others penetrate through it very poorly.
This distinction is of particular importance in the case of NAD+.
The fact that the patch works effectively for nicotine does not mean that the same simple delivery mechanism will be equally effective for the much larger and highly water-soluble NAD+ molecule.
Does NAD+ from the patch actually penetrate the skin?
Direct evidence showing significant absorption of NAD+ from standard passive adhesive patches is currently very limited.
This is the main weakness of the evidence base for this product category.
Particle size issue
The skin has been biologically adapted to act as a barrier.
Its outermost layer, the stratum corneum, limits the penetration of many substances from the external environment into the body.
One of the frequently cited principles in transdermal delivery research is the so-called 500-dalton rule. [1]
In accordance with this general principle, molecules that penetrate intact skin by passive diffusion usually have a molecular weight of less than approximately 500 daltons and, at the same time, possess favourable chemical properties, including adequate solubility in lipids.
This is not an absolute rule.
However, it provides a useful starting point when assessing whether a given substance is naturally suited for passive transdermal administration.
The molecular mass of NAD+ is approximately 663 daltons. [2]
This means that it exceeds the commonly accepted threshold for passive diffusion.
NAD+ also poses a second problem.
It is a strongly polar, charged and highly water-soluble molecule, rather than a small fat-soluble compound.
The stratum corneum of the skin is particularly effective at limiting the passage of large and strongly hydrophilic molecules.
The combination of NAD+’s relatively high molecular weight and its high polarity therefore provides a pharmacologically sound basis for questioning whether significant amounts of unchanged NAD+ can penetrate healthy skin when using a standard adhesive plaster.
This does not mean that absorption is impossible.
It means, however, that successful delivery must be directly demonstrated rather than merely assumed.
Can transdermal absorption be increased?
Yes.
Various technologies have been developed to improve the delivery of substances that, on their own, do not penetrate the skin very well.
These include iontophoresis, microneedle systems, chemical penetration enhancers, ultrasound-assisted methods and other specialist technologies.
Iontophoresis uses a low-intensity electric current to facilitate the movement of charged molecules through the skin.
This is particularly significant for NAD+, as the main published human study on transdermal NAD+ used iontophoresis rather than a standard passive patch. [3]
The study included people with persistent fatigue following COVID-19.
Participants received NAD+ via iontophoresis patches in combination with a low oral dose of naltrexone.
The researchers reported an improvement in fatigue scores and quality of life.
However, the study does not allow one to conclude that it was the NAD+ patch that was responsible for this improvement.
It was an open-label trial, did not include a placebo group, and involved two interventions simultaneously.
The very fact that iontophoresis was used is also significant, as it means that the results cannot be taken as proof of the effectiveness of ordinary passive NAD+ patches sold online.
Pharmacologically, an electrostimulated patch and a standard adhesive patch are different delivery systems.
What about standard commercial NAD+ patches?
Many consumer NAD+ patches appear to rely mainly on the passive diffusion of ingredients from the adhesive layer.
Product descriptions do not always clearly indicate whether specialised technologies enhancing penetration have been used.
A lack of such formulation details makes it difficult to compare products.
Most importantly, no published controlled human study has been identified that used a typical passive NAD+ patch and subsequently demonstrated a significant increase in blood or tissue NAD+ compared with placebo.
This is precisely the most important missing piece of information.
Without direct pharmacokinetic measurements, it is not known what amount of unchanged NAD+, if any, enters the systemic circulation from such products.
Current evidence therefore warrants caution.
NAD+ patches are commercially available, but effective passive delivery of unchanged NAD+ through the skin has not been convincingly demonstrated in controlled human studies.
Why are NAD+ and berberine combined in one patch?
NAD+ and berberine are often combined because both compounds appear in research on metabolism and longevity, although they work through very different biological mechanisms.
Berberine is a plant-derived alkaloid found in several plants traditionally used in herbal medicine.
Contemporary scientific literature on berberine focuses primarily on glucose regulation, lipid metabolism, insulin sensitivity, and related metabolic pathways.
One of the most frequently discussed mechanisms is AMPK, or AMP-activated protein kinase.
AMPK acts as an important cellular energy status sensor.
NAD+, on the other hand, acts as a coenzyme in energy metabolism and is required by NAD+-dependent enzymes such as sirtuins.
Because both the AMPK and sirtuin pathways are involved in the broad regulation of cellular energy, combining berberine with NAD+ may appear biologically complementary.
This is, however, a mechanistic justification.
This is not proof of synergy.
No controlled human trial has been identified that specifically evaluates a transdermal patch containing NAD+ and berberine.
Claims that these two ingredients work better together in a patch are therefore not currently supported by direct clinical studies.
Such a comparison also makes sense from a marketing perspective.
Both compounds are frequently promoted in terms of metabolic health, anti-aging, cellular energy and longevity.
Combining them in a single product allows the manufacturer to address several related wellness themes at the same time.
However, the question of transdermal delivery effectiveness should be evaluated separately for each ingredient.
Berberine and transdermal delivery
Berberine is a much smaller molecule than NAD+.
Depending on the specific chemical form, commonly used berberine salts have a molecular mass of approximately 336–390 daltons.
This means that in terms of size alone, they are below the 500-dalton threshold frequently discussed in the context of passive transdermal permeation.
However, molecular weight alone does not guarantee effective absorption through the skin.
Lipophilicity, the degree of ionisation, the formulation, the concentration, the condition of the skin and the patch technology used are also important factors.
The key point, therefore, is that the same patch does not necessarily deliver NAD+ and berberine with the same level of effectiveness.
Their chemical properties differ distinctly.
The presence of both ingredients on the label does not, therefore, prove that each of them enters the systemic circulation in a significant or comparable quantity.
How are NAD+ patches usually used?
There is no standardised and clinically validated protocol for the use of NAD+ patches comparable to the information contained in the summary of product characteristics of an approved transdermal medicinal product.
Commercial instructions vary from one manufacturer to another.
The following information describes typical manufacturer practices rather than an approved clinical protocol for NAD+.
Site of application
Manufacturers usually recommend applying the patch to relatively clean, dry and hairless skin.
The most commonly suggested sites include the upper arm, shoulder, abdomen or thigh.
The main aim is to ensure that the plaster adheres well and maintains firm contact with the skin.
It is usually avoided to apply it to damaged or irritated skin.
A break in the skin’s integrity may increase irritation whilst, at the same time, altering absorption in an unpredictable manner.
How long to wear the plaster
The recommended wearing time varies considerably between products.
Some manufacturers recommend a few hours.
Others suggest leaving the patch on for most of the day or even for up to around 24 hours.
Such periods are usually set by the manufacturer.
They should not be interpreted as pharmacokinetically validated NAD+ delivery periods, unless the specific formulation has been directly tested.
At present, there is little published data indicating how quickly unchanged NAD+ might enter the circulation from a passive patch, when systemic concentrations would peak, or how long they would remain at an elevated level.
Changing the application’s location
It is often recommended to rotate the site where the plaster is applied.
Regularly applying the adhesive layer to the same area of skin can increase the risk of local irritation.
The same principle applies to approved transdermal products, such as nicotine patches.
However, changing the location does not increase the evidence for NAD+ absorption.
It is primarily a practical way of limiting repeated skin contact with the same area.
Skin condition
Plasters are usually intended for use on unbroken skin.
Recently shaved, inflamed, damaged, sunburned or otherwise irritated skin may be more sensitive to the adhesive and may also alter absorption.
As detailed pharmacokinetic data regarding NAD+ patches remain limited, product-specific instructions should take precedence over assumptions based on other transdermal systems.
NAD+ patches vs capsules vs injections: which form delivers more?
There is currently no strong head-to-head human study comparing NAD+ patches, oral NAD+ precursors, and injectable NAD+ under identical conditions.
However, the quality of the evidence for the individual routes of administration varies considerably.
Oral capsules and tablets
Oral products containing NAD+ precursors, such as NR and NMN, currently have the strongest human research base.
Many randomised placebo-controlled trials have shown that oral NR and NMN can increase circulating NAD+ or related metabolites. [4]
This does not prove that these compounds improve every health parameter associated with NAD+ biology.
However, their impact on NAD+-related biomarkers has been confirmed numerous times.
Injectable and intravenous NAD+
Injections and IV infusions bypass the digestive tract.
From the delivery method point of view, it is a relatively simple solution.
However, controlled evidence regarding clinical outcomes in wellness and anti-aging applications remains limited.
A 2026 systematic review found no eligible controlled trials regarding intravenous or intramuscular NAD+ specifically for anti-ageing or general wellness applications. [5]
The commercial popularity of IV NAD+ therapy currently outpaces the strength of controlled clinical evidence supporting these uses.
NAD+ transdermal patches
Plasters are encountering an additional problem.
Unlike the IV infusion, which places NAD+ directly into the bloodstream, a passive patch must first allow the molecule to cross the skin barrier.
The relatively large molecular mass of NAD+ and its high polarity hinder this process from a basic pharmacological point of view.
One significant human study used iontophoresis instead of a standard passive patch. [3]
At the same time, NAD+ was used in it along with a low dose of naltrexone, and the study did not have a placebo group.
In the case of ordinary adhesive patches, no controlled human studies have been identified demonstrating a reliable increase in NAD+ in blood or tissues.
Based on current evidence, oral NAD+ precursors have significantly stronger validation for measurably increasing NAD+ than passive transdermal patches.
NAD+ patches vs capsules vs IV — a comparison
| Feature | NAD+ patches | Oral NR/NMN | Injectable/IV NAD+ |
|---|---|---|---|
| Main ingredient | Usually NAD+, sometimes combinations | NAD+ precursors | NAD+ |
| Application route | Through the skin | Absorption from the gastrointestinal tract | Injection or directly into the bloodstream |
| It bypasses the digestive system | Yes, if it is absorbed | Not | Yes |
| Main absorption barrier | Skin | alimentary canal | Absence of skin and gastrointestinal barriers |
| Strong human biomarker data | Not established for passive patches | Yes | Restricted for typical wellness protocols |
| Randomised human trials | Very limited | The strongest base among these forms | Limited |
| Iontophoresis studies | Yes, one small and constrained study [3] | Not applicable | Not applicable |
| Pharmacokinetics of a passive patch | Not set | Not applicable | Not applicable |
| Requires a clinic | Not usually | Not | Usually, yes |
| Proof of delivery | Not | An increase in NAD+ has been demonstrated | Direct administration, but clinical superiority has not been demonstrated |
Therefore, the most important question regarding patches is not whether transdermal delivery can work at all.
The point is whether this specific molecule can be delivered in a significant amount by a specific formulation.
In the case of standard NAD+ patches, this remains insufficiently proven.
What do NAD+ patch reviews really say?
Consumer reviews of NAD+ patches often describe subjective changes relating to energy levels, mood, tiredness, concentration or general well-being.
In the case of NAD+ patches with berberine, some reviews also mention appetite or metabolism.
Such experiences can be significant for the person describing them.
However, they do not constitute pharmacological evidence of absorption or clinical efficacy.
Why are user reviews difficult to interpret?
Consumer experiences are not collected in controlled conditions.
There is usually no placebo group.
The person knows that they are using a given product.
At the same time, other supplements, medications, diet, sleep quality, physical activity, caffeine intake, and natural day-to-day well-being may change.
Expectations can also affect the subjective assessment of parameters such as energy, mood or fatigue.
Another problem is the selection of people publishing reviews.
People who notice very positive or very negative experiences may be more inclined to leave a review than those who did not notice a significant difference.
Product reviews therefore provide information on consumer experiences.
They do not prove that unchanged NAD+ penetrated the skin or that it increased cellular NAD+ levels.
This is particularly significant because the very nature of NAD+ raises doubts as to whether it can pass passively through the skin.
A positive user review cannot resolve this pharmacological uncertainty.
To demonstrate actual absorption, researchers would need to measure NAD+ or relevant metabolites in the blood or tissues after applying the patch and compare the results with a placebo under controlled conditions.
There is still a significant lack of such studies on standard passive NAD+ patches.
Frequently asked questions about NAD+ patches
Do NAD+ patches really work?
It has not been clearly demonstrated that ordinary passive NAD+ patches deliver significant amounts of unchanged NAD+ through human skin.
NAD+ has a mass greater than approximately 500 daltons, which is the value often indicated as the practical limit for passive transdermal penetration, and in addition, it is strongly polar. [1,2]
There are a lack of direct pharmacokinetic studies on typical consumer patches.
Can NAD+ be absorbed through the skin?
Potentially yes, but the delivery technology matters a lot.
In one human study, iontophoresis was used to assist the transdermal delivery of NAD+. [3]
This does not prove equivalent absorption from simple adhesive patches without an active penetration-enhancing system.
What is the 500 dalton rule?
The 500-dalton rule is a frequently cited principle in transdermal delivery science, according to which passive skin penetration becomes increasingly difficult for molecules larger than about 500 daltons. [1]
This is not a hard and fast rule.
However, it is a useful criterion for assessing the probability of effective passive absorption.
NAD+ has a molecular mass of approximately 663 daltons. [2]
Is there any scientific evidence to support NAD+ patches containing berberine?
There is no dedicated human clinical trial demonstrating the synergistic effect of a patch containing NAD+ and berberine.
Both ingredients have distinct biological rationales, but their combination in a single patch has not been clinically proven.
Does berberine penetrate the skin more easily than NAD+?
Its lower molecular weight makes passive transdermal absorption more likely, simply because of the size of the molecule itself.
Effective absorption through the skin, however, depends on many other factors.
To determine how much berberine a specific patch actually delivers, a proper pharmacokinetic study would still be required.
Are NAD+ patches better than capsules?
This has not been demonstrated.
Oral NR and NMN have significantly stronger randomised human data showing a measurable increase in NAD+-related biomarkers. [4]
Comparable data are lacking for standard passive NAD+ patches.
Are NAD+ patches better than IV NAD+?
There is no direct human study to confirm this.
An IV infusion bypasses the skin barrier and delivers NAD+ directly into the bloodstream, whereas a patch requires absorption through the skin.
At the same time, IV NAD+ also has limited controlled data regarding clinical outcomes in anti-aging and wellness applications. [5]
Can consumer reviews prove that a patch is absorbed?
No.
Reviews may describe subjective experiences, but they cannot demonstrate systemic absorption, blood concentration or changes in cellular NAD+.
Controlled pharmacokinetic studies are needed to answer these questions.
Limitations of current evidence
The main limitation is the lack of direct pharmacokinetic data in humans on conventional passive NAD+ patches.
No controlled study measuring NAD+ in blood or tissues following the application of a simple adhesive patch of the type commonly offered to consumers has been identified.
The main question regarding absorption therefore remains unresolved.
The second limitation is the available transdermal study in humans.
It utilised iontophoresis, that is, an active delivery method, rather than simple passive diffusion. [3]
Participants also received an oral low dose of naltrexone.
The study was open-label and did not include a placebo group.
It therefore does not allow to determine whether the same NAD+ was responsible for the observed improvement.
The third limitation is products combining NAD+ and berberine.
No dedicated clinical trial has been identified that evaluates this combination in the form of a patch.
Separate studies on the biology of NAD+ and the metabolism of berberine should not be combined and presented as evidence supporting the synergistic effect of the transdermal mixture.
The 500-dalton rule also has its limitations.
It is a general guideline, not an absolute physical barrier. [1]
Advanced formulation technologies can enhance the delivery through the skin of substances that would otherwise be poorly absorbed.
However, it is often unclear whether specific commercial NAD+ patches actually utilise such technologies and whether they deliver clinically significant amounts of NAD+.
Finally, consumer reviews are a poor source of information on absorption.
Subjective reports do not allow us to distinguish between a pharmacological effect and a placebo, natural changes in well-being, simultaneous lifestyle changes, the effects of other patch ingredients, or selection bias among those publishing reviews.
Current evidence therefore justifies describing passive NAD+ patches as a convenient yet poorly validated delivery method, the ability of which to significantly increase systemic NAD+ has not yet been convincingly demonstrated.
Disclaimer
This article is intended solely for educational and scientific-informational purposes. It does not constitute medical advice, therapeutic recommendations, dosage instructions, advice on product selection, or recommendations regarding the use of NAD+ patches, berberine patches, products combining NAD+ with berberine, or other transdermal supplements.
The mere fact that NAD+ patches are commercially available does not prove that unmodified NAD+ is absorbed through the skin in clinically significant quantities. Furthermore, results relating to iontophoresis-assisted delivery should not be automatically extrapolated to standard passive adhesive patches, as these are different technologies.
NAD+, berberine and combination products containing these ingredients in patch form are not approved by the FDA or EMA to treat, prevent or cure diseases. Claims regarding increased energy, anti-ageing effects, metabolic enhancement, detoxification or disease treatment should be evaluated independently of data confirming transdermal absorption alone.
Pregnant or breastfeeding women, people with diabetes or other significant metabolic disorders, and those taking glucose-lowering medicines, cardiovascular medicines, anticoagulants or other prescription medicines should discuss the use of products containing berberine or NAD+ with a suitably qualified healthcare professional. Persistent skin irritation or other unexpected symptoms following the use of the patch also require appropriate assessment.
References
[1] Bos, J. D., & Meinardi, M. M. H. M. (2000). The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology, 9(3), 165–169. https://doi.org/10.1034/j.1600-0625.2000.009003165.x
[2] Yoshino, J., Baur, J. A., & Imai, S. (2018). NAD+ intermediates: The biology and therapeutic potential of NMN and NR. Cell Metabolism, 27(3), 513–528. https://doi.org/10.1016/j.cmet.2017.11.002
[3] Isman, A., Nyquist, A., Strecker, B., Harinath, G., Lee, V., Zhang, X., & Zalzala, S. (2024). Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms following COVID-19. Brain, Behavior, & Immunity – Health, 36, 100733. https://doi.org/10.1016/j.bbih.2024.100733
[4] Yi, L., Maier, A. B., Tao, R., Lin, Z., Vaidya, A., Pendse, S., Thasma, S., Andhalkar, N., Avhad, G., & Kumbhar, V. (2022). The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: A randomised, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience, 45, 29–43. https://doi.org/10.1007/s11357-022-00705-1
[5] Gallagher, C., & Emmanuel, O. O. (2026). NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Research Reviews, 116, 103057. https://doi.org/10.1016/j.arr.2026.103057